NCT07726966
Betacyanin for Early Diagnosis and Recovery of Anastomotic Leakage After Rectal Cancer Surgery: A Single-Center, Prospective, Controlled Trial
Not Yet Recruiting · Not Applicable · Southwest Hospital, China · registry updated 2026-07-27
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This single-center, prospective, controlled trial compares betacyanin versus conventional methods for early diagnosis and healing assessment of anastomotic leakage after rectal cancer surgery.
Inclusion
- Pathologically confirmed rectal adenocarcinoma prior to surgery.
- Undergoing laparoscopic anterior resection for rectal cancer.
- No prophylactic diverting ileostomy.
- American Society of Anesthesiologists (ASA) Physical Status Classification ≤ 3.
- No prior history of malignant tumors, and no evidence of other malignancies on preoperative examination.
- Written informed consent obtained from the patient or a legally authorized representative.
Exclusion
- Prior abdominal surgery with severe intra-abdominal adhesions.
- Currently participating in, or having participated within the past 6 months in, another clinical study related to rectal cancer surgery.
- Preoperative complications requiring emergency surgery, including bleeding, perforation, or obstruction.
- History of prior malignancy.
- Undergoing Parks procedure with anastomosis at the anal verge, or Miles procedure, or Hartmann's procedure.
- Preoperative neoadjuvant chemoradiotherapy, or presence of other high-risk factors for anastomotic leakage requiring a prophylactic diverting ileostomy.